vs
Employers Holdings, Inc.（EIG）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Employers Holdings, Inc.的1.3倍（$219.9M vs $170.5M），Orthofix Medical Inc.同比增速更快（2.0% vs -21.3%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -11.4%）
Employers Holdings, Inc.是总部位于美国的保险控股企业，主营劳工赔偿保险产品，主要面向美国境内中小微企业客户，同时提供定制化风险管理解决方案，服务覆盖多类中低风险行业，助力客户管控工作场所安全风险、满足员工保障相关合规要求。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
EIG vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$170.5M
营收增速更快
OFIX
高出23.3%
-21.3%
两年增速更快
OFIX
近两年复合增速
-11.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $170.5M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | -21.3% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EIGOFIX
| Q1 26 | $170.5M | — | ||
| Q4 25 | $188.5M | $219.9M | ||
| Q3 25 | $239.3M | $205.6M | ||
| Q2 25 | $246.3M | $203.1M | ||
| Q1 25 | $202.6M | $193.6M | ||
| Q4 24 | $216.6M | $215.7M | ||
| Q3 24 | $224.0M | $196.6M | ||
| Q2 24 | $217.0M | $198.6M |
净利润EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-8.3M | $-22.8M | ||
| Q2 25 | $29.7M | $-14.1M | ||
| Q1 25 | $12.8M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $30.3M | $-27.4M | ||
| Q2 24 | $31.7M | $-33.4M |
毛利率EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | -4.7% | -8.3% | ||
| Q2 25 | 15.0% | -7.9% | ||
| Q1 25 | 7.8% | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | 16.4% | -9.6% | ||
| Q2 24 | 18.4% | -12.5% |
净利率EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | -1.0% | ||
| Q3 25 | -3.5% | -11.1% | ||
| Q2 25 | 12.1% | -6.9% | ||
| Q1 25 | 6.3% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 13.5% | -13.9% | ||
| Q2 24 | 14.6% | -16.8% |
每股收益（稀释后）EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-0.93 | $-0.05 | ||
| Q3 25 | $-0.36 | $-0.57 | ||
| Q2 25 | $1.23 | $-0.36 | ||
| Q1 25 | $0.52 | $-1.35 | ||
| Q4 24 | $1.14 | $-0.76 | ||
| Q3 24 | $1.21 | $-0.71 | ||
| Q2 24 | $1.25 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $169.9M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $955.7M | $450.0M |
| 总资产 | $3.4B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EIGOFIX
| Q1 26 | $169.9M | — | ||
| Q4 25 | $169.9M | $82.0M | ||
| Q3 25 | $172.4M | $62.9M | ||
| Q2 25 | $78.1M | $65.6M | ||
| Q1 25 | $100.4M | $58.0M | ||
| Q4 24 | $68.4M | $83.2M | ||
| Q3 24 | $173.9M | $30.1M | ||
| Q2 24 | $126.4M | $26.4M |
总债务EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | $19.0M | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $0 | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益EIGOFIX
| Q1 26 | $955.7M | — | ||
| Q4 25 | $955.7M | $450.0M | ||
| Q3 25 | $1.0B | $442.5M | ||
| Q2 25 | $1.1B | $458.3M | ||
| Q1 25 | $1.1B | $458.3M | ||
| Q4 24 | $1.1B | $503.1M | ||
| Q3 24 | $1.1B | $525.9M | ||
| Q2 24 | $1.0B | $546.0M |
总资产EIGOFIX
| Q1 26 | $3.4B | — | ||
| Q4 25 | $3.4B | $850.6M | ||
| Q3 25 | $3.5B | $832.6M | ||
| Q2 25 | $3.5B | $837.2M | ||
| Q1 25 | $3.6B | $823.1M | ||
| Q4 24 | $3.5B | $893.3M | ||
| Q3 24 | $3.6B | $867.9M | ||
| Q2 24 | $3.5B | $882.0M |
负债/权益比EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | 0.02× | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 0.00× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | $44.7M | $27.7M | ||
| Q3 25 | $29.4M | $12.4M | ||
| Q2 25 | $0 | $11.6M | ||
| Q1 25 | $14.6M | $-18.4M | ||
| Q4 24 | $76.4M | $23.7M | ||
| Q3 24 | $51.0M | $11.7M | ||
| Q2 24 | $11.7M | $9.0M |
自由现金流EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | $44.6M | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | $76.3M | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K |
自由现金流率EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | 23.7% | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | 35.2% | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% |
资本支出强度EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% |
现金转化率EIGOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 1.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.68× | — | ||
| Q2 24 | 0.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EIG
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
